WenxingFeng

Experience

Valmet acquires process gas chromatography business of Siemens AGJones Day advised Valmet Oyj in the €102.5 million acquisition of the process gas chromatography business of Siemens AG.

CMBC International Capital Limited underwrites US$69 million IPO by Star Plus Legend Holdings LimitedJones Day represented CMBC International Capital Limited in connection with the approximately US$69 million initial public offering of Ordinary Shares of Star Plus Legend Holdings Limited listed on The Stock Exchange of Hong Kong Limited.

Hong Kong and China Power Holdings invests in Luquos Holding Limited (Luquos Cayman) seed roundJones Day represented Hong Kong and China Power Holdings Company Limited in the series seed round of financing of Luquos Holding Limited (Luquos Cayman).

Albaugh acquires RotamJones Day advised Albaugh, LLC in the $197.5 acquisition of Rotam Global AgroSciences Limited, a company headquartered in Hong Kong and publicly listed on the Taiwan Stock Exchange.

LeaderMed Health Group expands pipeline with Aqualung licenseJones Day represented LeaderMed Health Group Limited in subscription of a convertible note and an exclusive license agreement with Aqualung Therapeutics Corporation ("Aqualung") to develop, manufacture, and commercialize Aqualung's clinical stage antibody product ALT-100 in eight Asian territories, including Greater China.

Samson Paper Holdings Limited completes US$385 million cross-border restructuringJones Day advised Samson Paper Holdings Limited (the "Company"), a Bermuda incorporated company listed on the Main Board of the Stock Exchange of Hong Kong in connection with its US$385 million Bermuda/Mainland China/Hong Kong cross-border restructuring deal (the "Restructuring").

LeaderMed Health Group Limited enters into joint venture and licensing agreement with OPKO Health to develop and commercialize innovative drugs in Asian countriesJones Day represented LeaderMed Health Group Limited in the formation of a joint venture and exclusive license agreement with OPKO Health, Inc. ("OPKO") to develop, manufacture, and commercialize two of OPKO's clinical stage, long-acting drug products, Oxyntomodulin and Factor VIIa-CTP, in Greater China and eight other Asian territories.

GenScript Biotech and its subsidiaries Legend Biotech and ProBio Cayman complete US$1.07 billion investment by Hillhouse CapitalJones Day represented GenScript Biotech Corporation (“GenScript Biotech”), its controlling shareholder GenScript Corporation, and its two subsidiaries Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) and Probio Technology Limited (“Probio Cayman”) in connection with a US$1.07 billion investment by Hillhouse Capital.

Best Courage Global participates in Series A financing round of Aland Health Holding Ltd.Jones Day represented Best Courage Global Limited in connection with the Series A financing round of Aland Health Holding Ltd., a designer, manufacturer, seller and distributor of vitamins and other health and nutrition supplements and a provider of nutrition management solutions.

GenScript Biotech Corporation completes US$423.8 million IPO and spin-off of its subsidiary Legend Biotech Corporation; and US$24 million purchase of Ordinary Shares of Legend BiotechJones Day acted as the U.S. and Hong Kong legal advisors of GenScript Biotech Corporation (“GenScript Biotech”) in relation to its (a) approximately US$423.8 million initial public offering of 18,425,000 American Depositary Shares and spin-off listing of its subsidiary Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”) on the Nasdaq Global Select Market and (b) approximately US$24 million purchase of Ordinary Shares of Legend Biotech in a concurrent private placement of Legend Biotech.

GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.

GenScript Biotech Corporation completes placement of sharesJones Day advised GenScript Biotech Corporation (the “GenScript”, together with its subsidiaries, the “GenScript Group”), a company listed on The Stock Exchange of Hong Kong Limited, on its US$255 million top-up placing of shares and Ms. Ye Wang, a director, president, and controlling shareholder of GenScript on her US$51 million placing of shares.

CCB International Asset Management invests in Xinming China Holdings LimitedJones Day represented CCB International Asset Management Limited in connection with its investment in Xinming China Holdings Limited, an investment holding company principally engaged in property development, via the purchase of convertible bonds.

Haitong International Financial Products invests $25 million in Youyuan International HoldingsJones Day represented Haitong International Financial Products (Singapore) Pte Ltd in connection with its subscription of $25 million of Notes in Youyuan International Holdings Limited, a China-based wrapping tissue paper manufacturer.

Haitong International Financial Products invests $20 million in Burwill Holdings LimitedJones Day represented Haitong International Financial Products (Singapore) Pte Ltd in connection with its subscription of $20 million of 7% Convertible Bonds in Burwill Holdings Limited, a Hong Kong-based investment holding company principally engaged in steel trading.

The following represents experience acquired prior to joining Jones Day.

Represented the sole sponsor, Haitong International Capital Limited, and the underwriters, Haitong International Securities Company, J.P. Morgan Securities (Asia Pacific), J.P. Morgan Securities, KGI Capital Asia, and RHB Securities Hong Kong, in relation to life science research and application services company Genscript Biotech Corporation's HK$524million IPO on The Stock Exchange of Hong Kong.

Represented Haitong International Securities Company Limited as underwriter in relation to the listing of BBI Life Sciences Corporation (a Chinese company that develops, manufactures, and sells life sciences products used in scientific research) on the Main Board of The Stock Exchange of Hong Kong.

Represented China CNR Corporation Limited (a rolling stock manufacturer) in its US$1.2 billion H-share IPO on The Stock Exchange of Hong Kong.

Represented CICC, UBS, and RBS as joint bookrunners on the US$300 million initial public offering and Rule 144A/Regulation S global offering of Guodian Technology and Environment Group Corporation Limited (the largest environmental protection and energy conservation solutions provider for coal-fired power plants operating in China).

Represented CCB International Asset Management Limited and Credit China Holdings Limited in its investment in Firefly Games through the subscription of US$10 million Series B preferred shares issued by the parent company. Firefly Games is a U.S.-based company that primarily engages in third-party distribution of games, independent R&D, and BI tools and systems for games and other business. The company obtained the exclusive authorization for its game distribution rights in China from DreamWorks to make 12 animations into mobile phone games, including Kung Fu Panda, How to Train Your Dragon, Shrek, Madagascar, and other famous intellectual properties.

Represented Crosby Securities Limited as placing agent on the issue of a bond of HK$100 million by Skyfame Realty (Holdings) Limited (Stock Code: 59), a company listed on the Main Board of The Stock Exchange of Hong Kong. The listed company is principally engaged in property development, property investment, hotel operation, and provision of ancillary services in Hong Kong and the PRC.

Represented CCB International Asset Management Limited on its HK$100 million pre-IPO investment in a PRC-based company by way of subscription of strict bond and exchangeable bond issued by its controlling shareholder. The company is primarily focused on the manufacturing and sales of plasma-derived biopharmaceuticals in China.

Represented financial advisor Haitong International Capital Limited in the acquisition by Leyou Technologies Holdings Limited (which engages in the development, distribution, and operation of online games), including the completed acquisition of Digital Extremes, a Canadian online game developer and operator, and its subsidiaries, and the acquisition of Splash Damage Limited, Warchest Limited, and Fireteam Limited in the U.K., for a total consideration of approximately US$160 million. Leyou Technologies (Stock Code: 1089) is listed on the Main Board of The Stock Exchange of Hong Kong.